# Why RFK Jr.’s firing of FDA experts likely won’t improve public trust > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/fda-regulation-policy-clinical-practice-impact-cannabis/ > **Published:** 2026-03-26T15:03:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:18:16-04:00 > **Clinical Summary:** Explore how FDA regulation policy clinical practice affects cannabis medicine oversight and patient safety amid recent leadership changes. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic [Fda Regulation](https://cedclinic.com/fda-warning-on-cbd-products/)PolicyClinical PracticePatient SafetyResearch Oversight Why This Matters Regulatory upheaval at FDA directly impacts [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) oversight, from research approval to product safety standards. [Clinical cannabis](https://cedclinic.com/entourage-effect-cannabis-clinical-breeding-benefits/) practice depends on consistent, science-based regulatory frameworks that protect patients while enabling access to evidence-backed treatments. Clinical Summary The article discusses potential FDA leadership changes under RFK Jr.’s influence, focusing on concerns about regulatory capture and industry influence. While the piece addresses broader FDA oversight issues, it highlights tensions between public health protection and industry interests. The [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) field operates within this same regulatory environment, where FDA decisions on research protocols, product classifications, and safety standards directly affect clinical practice and patient access. Dr. Caplan’s Take “Cannabis medicine has suffered from regulatory inconsistency for decades—what we need is more rigorous science, not more political interference. Any FDA changes must prioritize evidence-based decision making over ideology, regardless of which industry or advocacy group is pushing.” Clinical Perspective 🧠 Clinicians should monitor how regulatory changes affect [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) approval processes and product safety oversight. Focus on evidence-based prescribing practices and established clinical protocols rather than regulatory speculation. [Patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions should remain grounded in available clinical evidence, not political developments. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Why%20RFK%20Jr.%27s%20firing%20of%20FDA%20experts%20likely%20won%27t%20improve%20public%20trust%20%40drcaplan&url=https%3A//priceschool.usc.edu/news/fda-conflicts-interest-rfk-industry-influence/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//priceschool.usc.edu/news/fda-conflicts-interest-rfk-industry-influence/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Why%20RFK%20Jr.%27s%20firing%20of%20FDA%20experts%20likely%20won%27t%20improve%20public%20trust%20--%20via%20%40drcaplan.bsky.social%20https%3A//priceschool.usc.edu/news/fda-conflicts-interest-rfk-industry-influence/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://priceschool.usc.edu/news/fda-conflicts-interest-rfk-industry-influence/](https://priceschool.usc.edu/news/fda-conflicts-interest-rfk-industry-influence/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What type of cannabis-related content does this article cover?](#What_type_of_cannabis-related_content_does_this_article_cover) - [Why is this article tagged with “Patient Safety”?](#Why_is_this_article_tagged_with_8220Patient_Safety8221) - [How does this relate to clinical practice?](#How_does_this_relate_to_clinical_practice) - [What should healthcare professionals do with this information?](#What_should_healthcare_professionals_do_with_this_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has received a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This means the content represents emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related content does this article cover? The article focuses on [FDA regulation](https://cedclinic.com/fda-warning-on-cbd-products/) and policy developments in cannabis. It appears to address regulatory changes that may impact clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). #### Why is this article tagged with “Patient Safety”? The patient safety tag indicates that the regulatory or policy changes discussed may have direct implications for patient care and safety. Healthcare providers should be aware of these developments to ensure appropriate patient management. #### How does this relate to clinical practice? This article is tagged for clinical practice, suggesting that the FDA regulatory changes or policy updates will likely affect how healthcare providers approach cannabis-related treatments. Clinicians may need to adjust their practices based on these developments. #### What should healthcare professionals do with this information? Given the “Notable Clinical Interest” rating, healthcare professionals should monitor these emerging FDA regulations and policy changes closely. They should stay informed about how these developments may impact their clinical decision-making and patient care protocols. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Why RFK Jr.’s firing of FDA experts likely won’t improve public trust”, “url”: “https://priceschool.usc.edu/news/fda-conflicts-interest-rfk-industry-influence/”, “datePublished”: “2026-03-26T15:23:13Z”, “about”: “why rfk jr s firing fda”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Health professionals say new rules gives government too much disciplinary power](https://cedclinic.com/regulatory-uncertainty-cannabis-prescribing/) Explore concerns from health professionals about new government disciplinary powers affecting clinical practice and regulatory oversight. [Read More](https://cedclinic.com/regulatory-uncertainty-cannabis-prescribing/) [Cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) is more than a scientific pursuit—it's a pathway to better health, informed … Discover how cannabis research advances clinical knowledge and informs safer patient care practices. Explore Research Meet The Cannabis Industry's Trump Whisperer – Forbes Insights into influential figures shaping cannabis industry policy and regulatory landscapes. Learn More ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).